Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Exelixis Inc. Common Stock (EXEL) vs S&P500 ETF (SPY) Price & Performance

Exelixis Inc. Common StockTrade
S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Exelixis Inc. Common Stock vs S&P500 ETF — how do they compare? Exelixis Inc. Common Stock trades at $58.58 (market cap $14.48B), while S&P500 ETF trades at $777.47 (market cap $819.04B). The key difference: S&P500 ETF is far larger — about 56.6× Exelixis Inc. Common Stock's market cap, and S&P500 ETF is more actively traded (30,746,070 versus 2,374,774). Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and S&P500 ETF for 205 Days on average.

EXELSPY
Market Cap
$14.48B$819.04B
Volume
2,374,77430,746,070
Sector
Health—
52-Week High
$59.13$779.14
52-Week Low
$34.54$631.99
Typical Hold Time
0 Days205 Days
Enterprise Value
$13.81B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Exelixis Inc. Common Stock

No Aura AI signal available yet.

S&P500 ETF

SPY, the SPDR S&P 500 ETF, trades at $777.26, down 0.24% on the day. The technical outlook is bullish, with moving averages strongly supportive and the price above key support at $775. However, oscillators are neutral, and the 6-day RSI at 75.74 suggests potential overbought conditions. A dividend of $1.89 is scheduled for payment on October 30, 2026.

The ETF's outlook remains tied to broader S&P 500 earnings, which are projected to grow 35% in 2026 but slow to 15% in 2027. Key risks include market-wide valuation concerns and potential profit growth deceleration. Investor sentiment is mixed, with some analysts highlighting defensive positioning and seasonal patterns favoring a year-end rally.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EXEL
100% Buy0% Sell
Avg holding period · 0 Days
SPY
75% Buy25% Sell
Avg holding period · 205 Days

About Exelixis Inc. Common Stock

Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.

Read more on EXEL →

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on SPY →